Core Insights - The Hong Kong Traditional Chinese Medicine (TCM) stocks showed strong performance, with China Traditional Chinese Medicine rising over 8% initially before settling at a 2.9% increase, while other stocks like Wei Yuan Tang and Tong Ren Tang Guo Yao also saw gains [1][2] Industry Developments - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Plan for High-Quality Development of the TCM Industry (2026-2030)" [1] - By 2030, a collaborative development system for the entire TCM industry chain is expected to be initially formed, with enhanced stable supply capabilities for key TCM raw materials and significant improvements in digitalization and greening levels [1] - The plan emphasizes the use of artificial intelligence and big data to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners [1] Policy Implications - Analysts view this plan as a systemic, long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" development [1] - The plan serves as a "general program" for the development of the TCM industry over the next five years, focusing on raising industry standards, encouraging innovation, and driving a profound supply-side reform [1]

Group 1 - The core viewpoint of the news is that the Chinese traditional medicine sector is experiencing a strong market response following the release of a new development plan by the Ministry of Industry and Information Technology and seven other departments, which aims to enhance the quality and innovation of the industry by 2030 [1] - The plan outlines that by 2030, a collaborative development system for the entire traditional Chinese medicine (TCM) industry chain will be initially formed, with a focus on stable supply of key TCM raw materials and significant improvements in digitalization and greening levels [1] - Analysts suggest that this plan represents a systematic and long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" growth, serving as a guiding framework for the development of the TCM industry over the next five years [1] Group 2 - The stock performance of TCM companies shows a positive trend, with China Traditional Chinese Medicine rising over 8% at one point, currently up by 2.9%, and other companies like Yuyuan Tang and Tong Ren Tang also experiencing gains [2] - Specific stock price changes include: Yuyuan Tang at 0.365 with a 5.80% increase, China Traditional Chinese Medicine at 2.130 with a 2.90% increase, and Fosen Pharmaceutical at 0.750 with a 1.35% increase [2] - Other companies such as Tong Ren Rong Guo Yao, Baiyun Mountain, Tong Ren Tang Technology, and Jilin Changlong Pharmaceutical also reported slight increases in their stock prices, indicating a broader positive sentiment in the TCM sector [2]

Core Viewpoint - The traditional Chinese medicine sector is experiencing active market performance, with several companies showing significant stock price increases amid broader market conditions [2] Company Performance - China Traditional Chinese Medicine (00570.HK) saw a stock price increase of 5.8%, reaching HKD 2.19 [2] - Yao Wang Tang (00897.HK) experienced a rise of 4.35%, with its stock priced at HKD 0.36 [2] - Tong Ren Tang Guo Yao (03613.HK) increased by 2.38%, trading at HKD 9.03 [2] - Tong Ren Tang Technology (01666.HK) rose by 1.83%, with a stock price of HKD 4.44 [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.01 HK ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.0 ...

WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位元堂藥業控股有限公司 *） 請注意， 閣下在填寫及交回非登記股東申請表格以索取本次公司通訊的印刷本後，即表示 閣下確認選擇 收取本公司所有日後公司通訊（2「公司通訊」）的印刷本。 倘 閣 下 對 本 通 知 有 任 何 疑 問，請 致 電 香 港 股 份 過 戶 登 記 分 處 諮 詢 熱 線(852) 2980 1333查 詢，辦 公 時 間 為 星期一至星期五（香港公眾假期除外）上午九時正至下午六時正。 （於百慕達註冊成立之有限公司） （股份代號：897） 各位非登記股東1： 於本公司網站刊登公司通訊之通知 謹此通知 閣下，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）之下述公司 通 訊（「本次公司通訊」）之英文及中文版本，現已於本公司網站www.wyth.net及香港聯合交易所有限公司（「聯 交 所」）網 站www.hkexnews.hk登載： 截至二零二五年九月三十日止六個月的中期報告 請 於 本 公 司 網 站「投 資 者 關 係」一 欄 或 ...

選擇公司通訊之收取方式及語言版本 為響應環保以提升與 閣下的溝通效率及節省印刷及郵遞費用，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）鼓勵及建議 閣下選擇收取於本公司網站 www.wyth.net本公司所有日後刊載之公司通訊（「公司通訊」）（「網上版本」）以代替印刷本。公司通訊 即本公司已刊發或將予刊發以供 閣下參照或採取行動之任何文件，包括但不限於：(a)董事會報 告、年度賬目連同獨立核數師報告及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報 告；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格。 根據香港聯合交易所有限公司（「聯交所」）證券上市規則第2.07A及2.07B條及遵守本公司的公司細 則，請 閣下填妥及簽署隨函附奉的回條（「回 條」），並將其寄回或親身交回本公司之香港股份過 戶及轉讓登記分處（「香港股份過戶登記分處」）卓佳證券登記有限公司（地址為香港夏愨道16號 遠 東金融中心17樓）或電郵至897-ecom@vistra.com。 倘本公司於二零二六年一月二十二日前尚未收到 閣下已填寫及簽 ...

謹此通知 閣下，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）之下述公司 通 訊（「本次公司通訊」）之英文及中文版本，現已於本公司網站www.wyth.net及香港聯合交易所有限公司（「聯 交 所」）網 站 www.hkexnews.hk登載；或 閣下所選擇之本次公司通訊之印刷本已隨函附上（如 閣下已選擇接 收本公司的公司通訊印刷版）： WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位元堂藥業控股有限公司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 各位現有登記股東： 於本公司網站刊登公司通訊之通知 附註： 公司通訊指本公司已刊發或將予刊發以供本公司證券持有人參照或採取行動之任何文件，包括但不限於：(a)董事會報告、年度賬 目連同獨立核數師報告及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；及 (f)代表委任表格。 * 僅供識別 截至二零二五年九月三十日止六個月的中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內或參考 ...

Content 目錄 C 錄 | CORPORATE INFORMATION | 公司資料 | 2 | | --- | --- | --- | | INTERIM DIVIDEND | 中期股息 | 5 | | MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | 5 | | DISCLOSURE OF INTERESTS | 權益披露 | 14 | | SHARE OPTION SCHEME | 購股權計劃 | 20 | | CORPORATE GOVERNANCE AND OTHER INFORMATION | 企業管治及其他資料 | 23 | | CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR | 簡明綜合損益及 | 25 | | LOSS AND OTHER COMPREHENSIVE INCOME | 其他全面收益表 | | | CONDENSED CONSOLIDATED STATEMENT OF | 簡明綜合財務狀況表 | 28 | | FINANCIAL POSITION | | | | CONDENSED ...

Group 1 - Xiamen Airport is planning to acquire 100% equity of Xiamen Zhaoxiang Technology Co., Ltd., a wholly-owned subsidiary of its controlling shareholder, Xiamen Xiangye Group, using its own funds [2][4] - The acquisition aims to extend the company's business into the civil aviation intelligence sector, responding to the planned closure of Xiamen Gaoqi International Airport by the end of 2026 [2][4][5] - Zhaoxiang Technology focuses on civil aviation information technology, smart airport system construction and operation, and building intelligence, covering areas such as civil aviation operations, logistics, safety, and management [6][4] Group 2 - Xiamen Airport's main business is divided into aviation-related and non-aviation-related operations, with aviation-related operations including passenger and cargo services [8] - In November, Xiamen Airport reported a passenger throughput of 2.3195 million, a year-on-year decrease of 1.33%, and a cargo and mail throughput of 30,600 tons, down 13.25% year-on-year [8] - For the first three quarters of the year, Xiamen Airport achieved a revenue of 1.523 billion yuan, a year-on-year increase of 7.21%, and a net profit attributable to shareholders of 384 million yuan, up 3.53% year-on-year [8][9]